In an ongoing phase I clinical trial (NCT05009966), 33 patients with advanced, heavily pretreated CLDN18.2-positive gastric or pancreatic cancer received SYSA1801 monotherapy. This evidence concerns the gene CLDN18 and familial pancreatic carcinoma.